280 related articles for article (PubMed ID: 33712891)
1. Association of anti-NXP2 antibody with clinical characteristics and outcomes in adult dermatomyositis: results from clinical applications based on a myositis-specific antibody.
Yan TT; Zhang X; Yang HH; Sun WJ; Liu L; Du Y; Xue J
Clin Rheumatol; 2021 Sep; 40(9):3695-3702. PubMed ID: 33712891
[TBL] [Abstract][Full Text] [Related]
2. Clinical profile of anti-NXP-2 antibody-positive inflammatory myositis and outcome in an Indian population.
Manwatkar A; Padiyar S; Nair A; Jha A; Kumar S; Yadav B; Prakash JAJ; Das JK; Mathew J
Clin Rheumatol; 2023 Dec; 42(12):3289-3297. PubMed ID: 37801141
[TBL] [Abstract][Full Text] [Related]
3. Four dermatomyositis-specific autoantibodies-anti-TIF1γ, anti-NXP2, anti-SAE and anti-MDA5-in adult and juvenile patients with idiopathic inflammatory myopathies in a Hungarian cohort.
Bodoki L; Nagy-Vincze M; Griger Z; Betteridge Z; Szöllősi L; Dankó K
Autoimmun Rev; 2014 Dec; 13(12):1211-9. PubMed ID: 25182203
[TBL] [Abstract][Full Text] [Related]
4. Interstitial lung disease in adult patients with anti-NXP2 antibody positivity: a multicentre 18-month follow-up study.
Yan T; Du Y; Sun W; Chen X; Wu Q; Ye Q; Chen S; Xue J
Clin Exp Rheumatol; 2023 Mar; 41(2):247-253. PubMed ID: 35819809
[TBL] [Abstract][Full Text] [Related]
5. Clinical Heterogeneity of Patients With Antinuclear Matrix Protein 2 Antibody-Positive Myositis: A Retrospective Cohort Study in China.
Li S; Sun C; Zhang L; Han J; Yang H; Gao S; He L; Zhang P; Lu X; Shu X; Wang G
J Rheumatol; 2022 Aug; 49(8):922-928. PubMed ID: 35705242
[TBL] [Abstract][Full Text] [Related]
6. An Italian Multicenter Study on Anti-NXP2 Antibodies: Clinical and Serological Associations.
Fredi M; Cavazzana I; Ceribelli A; Cavagna L; Barsotti S; Bartoloni E; Benucci M; De Stefano L; Doria A; Emmi G; Fabris M; Fornaro M; Furini F; Giudizi MG; Govoni M; Ghirardello A; Iaccarino L; Iannone F; Infantino M; Isailovic N; Lazzaroni MG; Manfredi M; Mathieu A; Marasco E; Migliorini P; Montecucco C; Palterer B; Parronchi P; Piga M; Pratesi F; Riccieri V; Selmi C; Tampoia M; Tripoli A; Zanframundo G; Radice A; Gerli R; Franceschini F;
Clin Rev Allergy Immunol; 2022 Oct; 63(2):240-250. PubMed ID: 35092577
[TBL] [Abstract][Full Text] [Related]
7. [The analysis of clinical phenotypes and autoantibodies in juvenile dermatomyositis].
Li DM; Wang L; Liu MY; Xu L; Tang XM
Zhonghua Er Ke Za Zhi; 2020 Dec; 58(12):966-972. PubMed ID: 33256317
[No Abstract] [Full Text] [Related]
8. Clinical value of cancer-associated myositis-specific antibodies, anti-transcriptional intermediary factor 1-γ, and anti-nuclear matrix protein 2 antibodies in a retrospective cohort of dermatomyositis/polymyositis in a Japanese community hospital.
Suga T; Oiwa H; Ishida M; Iwamoto Y
Clin Rheumatol; 2022 Sep; 41(9):2803-2808. PubMed ID: 35399148
[TBL] [Abstract][Full Text] [Related]
9. Recent research on myositis-specific autoantibodies in juvenile dermatomyositis.
He L
Zhongguo Dang Dai Er Ke Za Zhi; 2021 Oct; 23(10):1064-1068. PubMed ID: 34719424
[TBL] [Abstract][Full Text] [Related]
10. Severe gastrointestinal involvements in patients with adult dermatomyositis with anti-NXP2 antibody.
Fu Y; Gu L; Chen J; Dai Y; Feng Q; Chen Z; Fan J; Gao M; Wang X; Fu Q; Ye S
RMD Open; 2024 Jan; 10(1):. PubMed ID: 38199847
[TBL] [Abstract][Full Text] [Related]
11. The spectrum and clinical significance of myositis-specific autoantibodies in Chinese patients with idiopathic inflammatory myopathies.
Li S; Ge Y; Yang H; Wang T; Zheng X; Peng Q; Lu X; Wang G
Clin Rheumatol; 2019 Aug; 38(8):2171-2179. PubMed ID: 30863950
[TBL] [Abstract][Full Text] [Related]
12. [Clinical and immunological characteristics of myositis complicated with thromboembolism].
Zhu FY; Xing XY; Tang XF; Li YM; Shao M; Zhang XW; Li YH; Sun XL; He J
Beijing Da Xue Xue Bao Yi Xue Ban; 2020 Dec; 52(6):995-1000. PubMed ID: 33331304
[TBL] [Abstract][Full Text] [Related]
13. Clinical features, muscle biopsy scores, myositis specific antibody profiles and outcome in juvenile dermatomyositis.
Sag E; Demir S; Bilginer Y; Talim B; Haliloglu G; Topaloglu H; Ozen S
Semin Arthritis Rheum; 2021 Feb; 51(1):95-100. PubMed ID: 33360233
[TBL] [Abstract][Full Text] [Related]
14. Clinical subsets of juvenile dermatomyositis classified by myositis-specific autoantibodies: Experience at a single center in Japan.
Iwata N; Nakaseko H; Kohagura T; Yasuoka R; Abe N; Kawabe S; Sugiura S; Muro Y
Mod Rheumatol; 2019 Sep; 29(5):802-807. PubMed ID: 30092736
[No Abstract] [Full Text] [Related]
15. Anti-nuclear matrix protein 2 antibody-positive inflammatory myopathies represent extensive myositis without dermatomyositis-specific rash.
Ichimura Y; Konishi R; Shobo M; Inoue S; Okune M; Maeda A; Tanaka R; Kubota N; Matsumoto I; Ishii A; Tamaoka A; Shimbo A; Mori M; Morio T; Kishi T; Miyamae T; Tanboon J; Inoue M; Nishino I; Fujimoto M; Nomura T; Okiyama N
Rheumatology (Oxford); 2022 Mar; 61(3):1222-1227. PubMed ID: 34152410
[TBL] [Abstract][Full Text] [Related]
16. Comprehensive assessment of myositis-specific autoantibodies in polymyositis/dermatomyositis-associated interstitial lung disease.
Hozumi H; Fujisawa T; Nakashima R; Johkoh T; Sumikawa H; Murakami A; Enomoto N; Inui N; Nakamura Y; Hosono Y; Imura Y; Mimori T; Suda T
Respir Med; 2016 Dec; 121():91-99. PubMed ID: 27888997
[TBL] [Abstract][Full Text] [Related]
17. Possible correlation between serum interleukin-8 levels and the activity of myositis in anti-NXP2 antibody-positive dermatomyositis.
Konishi R; Ichimura Y; Tanaka R; Miyahara H; Okune M; Miyamoto M; Hara M; Iwabuchi A; Takada H; Nakagishi Y; Mizuta M; Kaneko S; Shimizu M; Morio T; Nishino I; Nomura T; Okiyama N
Immunol Med; 2024 Jun; 47(2):100-105. PubMed ID: 38174692
[TBL] [Abstract][Full Text] [Related]
18. Clinical characteristics and poor predictors of anti-NXP2 antibody-associated Chinese JDM children.
Wang X; Ding Y; Zhou Z; Hou J; Xu Y; Li J
Pediatr Rheumatol Online J; 2021 Jan; 19(1):6. PubMed ID: 33407621
[TBL] [Abstract][Full Text] [Related]
19. Specific autoantibodies in dermatomyositis: a helpful tool to classify different clinical subsets.
Merlo G; Clapasson A; Cozzani E; Sanna L; Pesce G; Bagnasco M; Burlando M; Parodi A
Arch Dermatol Res; 2017 Mar; 309(2):87-95. PubMed ID: 27928683
[TBL] [Abstract][Full Text] [Related]
20. Differential clinical features of patients with clinically amyopathic dermatomyositis who have circulating anti-MDA5 autoantibodies with or without myositis-associated autoantibodies.
Yamaguchi K; Yamaguchi A; Kashiwagi C; Sawada Y; Taguchi K; Umetsu K; Oshima K; Uchida M; Suzuki M; Kono S; Takemura M; Masubuchi H; Kitahara S; Hara K; Maeno T; Motegi SI; Muro Y; Sakairi T; Hisada T; Kurabayashi M
Respir Med; 2018 Jul; 140():1-5. PubMed ID: 29957268
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
